Total submissions: 23
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000000619 | SCV000852113 | pathogenic | Phenylketonuria | 2018-08-07 | reviewed by expert panel | curation | PAH-specific ACMG/AMP criteria applied: PVS1: nonsense variant; PS3: <1% of normal PAH activity (PMID:2014036). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PS3). |
Eurofins Ntd Llc |
RCV000078528 | SCV000110384 | pathogenic | not provided | 2013-06-20 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000000619 | SCV000375567 | pathogenic | Phenylketonuria | 2017-04-27 | criteria provided, single submitter | clinical testing | The PAH c.727C>T (p.Arg243Ter) variant is a stop gained variant that is predicted to result in premature termination of the protein. Across a selection of the available literature, the p.Arg243Ter variant has been identified in a total of 20 patients with phenylalanine hydroxylase deficiency leading to phenylketonuria, including in ten in a homozygous state and in ten in a compound heterozygous state (Wang et al. 1990; Ramus et al. 1993; Zurflüh et al. 2008; Zare-Karizi et al. 2011; Spaapen et al. 2011; Couce et al. 2013; Bashyam et al. 2014). Control data are unavailable for this variant from these studies, which is reported at a frequency of 0.00009 in the European (non-Finnish) population of the Exome Aggregation Consortium. Patients with the p.Arg243Ter variant showed reduced enzyme activity of < 1% of wild type (Zurflüh et al. 2008; Couce et al. 2013). Based on the collective evidence and the potential impact of stop-gained variants, the p.Arg243Ter variant is classified as pathogenic for phenylalanine hydroxylase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
Gene |
RCV000078528 | SCV000490681 | pathogenic | not provided | 2019-12-05 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Patients homozygous for the R243X variant are reported to have a classic PKU phenotype and are not responsive to BH4 therapy (Zurfluh et al., 2008); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 25525159, 26589311, 26210745, 30747360, 26655635, 23500595, 11486900, 24941924, 24130151, 17935162, 26759449, 27121329, 14741196, 2309142, 2014036, 28676969, 28540274, 29499199, 31355225, 26666653, 31589614) |
Labcorp Genetics |
RCV000000619 | SCV000629210 | pathogenic | Phenylketonuria | 2024-01-14 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg243*) in the PAH gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PAH are known to be pathogenic (PMID: 1301187, 9634518). This variant is present in population databases (rs5030846, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with PKU (PMID: 2014036, 11486900, 14741196, 17935162, 23500595, 24130151, 26666653; Invitae). ClinVar contains an entry for this variant (Variation ID: 588). For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000000619 | SCV000696462 | pathogenic | Phenylketonuria | 2017-08-22 | criteria provided, single submitter | clinical testing | Variant summary: The PAH c.727C>T (p.Arg243X) variant results in a premature termination codon, predicted to cause a truncated or absent PAH protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One truncation downstream of this position has been classified as pathogenic by our laboratory (c.1089delG, p.Lys363fsX37). One in silico tool predicts a damaging outcome for this variant. A functional study found this variant to be associated with in vitro hydroxylase activity <1% of normal levels (Okano_1991). This variant was found in the large control database ExAC in 6/121162 control chromosomes at a frequency of 0.0000495, which does not exceed the estimated maximal expected allele frequency of a pathogenic PAH variant (0.0079057). This variant has been reported in many affected individuals with phenylketonuria and hyperphenylalaninemia (Zurfluh_2008, Couce_2013). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. |
Ce |
RCV000078528 | SCV001370957 | pathogenic | not provided | 2020-05-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000000619 | SCV001810548 | pathogenic | Phenylketonuria | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002512610 | SCV003696594 | pathogenic | Inborn genetic diseases | 2021-04-20 | criteria provided, single submitter | clinical testing | The c.727C>T (p.R243*) alteration, located in exon 7 (coding exon 7) of the PAH gene, consists of a C to T substitution at nucleotide position 727. This changes the amino acid from a arginine (R) to a stop codon at amino acid position 243. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This mutation has been reported in multiple homozygous and compound heterozygous individuals with phenylalanine hydroxylase deficiency (Zare-Karizi, 2011; Couce, 2013; Aldámiz-Echevarría, 2016; Su, 2019). Based on the available evidence, this alteration is classified as pathogenic. |
Baylor Genetics | RCV000000619 | SCV004201323 | pathogenic | Phenylketonuria | 2024-03-16 | criteria provided, single submitter | clinical testing | |
Victorian Clinical Genetics Services, |
RCV000000619 | SCV005400552 | pathogenic | Phenylketonuria | 2024-10-08 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with phenylketonuria (MIM#261600). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (13 heterozygotes, 0 homozygotes). (SP) 0701 - Other NMD predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (DECIPHER). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant is classified as pathogenic by an expert panel in ClinVar and has been observed as homozygous or compound heterozygous in individuals with classical PKU (PMID: 26666653). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Mayo Clinic Laboratories, |
RCV000078528 | SCV005414115 | pathogenic | not provided | 2024-03-18 | criteria provided, single submitter | clinical testing | PM2_moderate, PM3, PS3, PVS1 |
Juno Genomics, |
RCV000000619 | SCV005416226 | pathogenic | Phenylketonuria | criteria provided, single submitter | clinical testing | PVS1+PM2_Supporting+PM3_VeryStrong | |
Al Jalila Children’s Genomics Center, |
RCV004798707 | SCV005420354 | pathogenic | Hyperphenylalaninemia | 2024-10-04 | criteria provided, single submitter | research | PVS1, PS3,PM2,PP4 |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000078528 | SCV005624695 | pathogenic | not provided | 2024-10-30 | criteria provided, single submitter | clinical testing | The PAH c.727C>T (p.Arg243*) variant causes the premature termination of PAH protein synthesis. In the published literature, this variant has been reported in individuals with phenylketonuria (PKU) and is associated with having nearly absent residual PAH activity (PMIDs: 31355225 (2019), 26666653 (2015), 24130151 (2014), 23500595 (2013), 17935162 (2008), 15589814 (2004), 14741196 (2004), 11486900 (2001), 2014036 (1991)). BH4-reponsiveness of this variant ranged from mildly responsive (PMIDs: 15589814 (2004), 14741196 (2004)) to nonresponsive (PMIDs: 26666653 (2015), 17935162 (2008)). The frequency of this variant in the general population, 0.000085 (11/128860 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as pathogenic. |
OMIM | RCV000000619 | SCV000020769 | pathogenic | Phenylketonuria | 1991-03-15 | no assertion criteria provided | literature only | |
De |
RCV000078528 | SCV000119664 | not provided | not provided | no assertion provided | not provided | ||
Counsyl | RCV000000619 | SCV001132445 | pathogenic | Phenylketonuria | 2014-01-02 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000000619 | SCV001453113 | pathogenic | Phenylketonuria | 2020-09-16 | no assertion criteria provided | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000078528 | SCV001926514 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000078528 | SCV001951335 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000078528 | SCV001973072 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003407250 | SCV004114446 | pathogenic | PAH-related disorder | 2024-07-16 | no assertion criteria provided | clinical testing | The PAH c.727C>T variant is predicted to result in premature protein termination (p.Arg243*). This sequence variant has been reported to be causative phenylalanine hydroxylase deficiency and has been associated with classical phenylketonuria (PKU) (e.g., Okano et al. 1991. PubMed ID: 2014036; Couce et al. 2013. PubMed ID: 23500595; Jeannesson-Thivisol et al. 2015. PubMed ID: 26666653). Patients with the c.727C>T variant have been reported to be non-responsive to tetrahydrobiopterin (BH4) (Zurflüh et al. 2008. PubMed ID: 17935162). Nearly one hundred patients homozygous for the c.727C>T (p.Arg243*) variant have been reported in the BioPKU database; all of these patients presented with classic PKU (http://www.biopku.org). In the ClinVar database, this variant is classified as pathogenic by the ClinGen PAH Variant Curation Expert Panel as well as multiple outside laboratories (https://www.ncbi.nlm.nih.gov/clinvar/variation/588/). Nonsense variants in PAH are expected to be pathogenic. Taken together, this variant is interpreted as pathogenic. |